Detalhe da pesquisa
1.
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Cancer
; 123(23): 4617-4630, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817190
2.
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Cancer
; 122(21): 3327-3335, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27433944
3.
A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.
Bioorg Med Chem Lett
; 18(21): 5763-5, 2008 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18842409
4.
Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.
Bioorg Med Chem Lett
; 18(23): 6236-9, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18926699
5.
Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
Mol Cancer Ther
; 9(7): 2046-56, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20571074
6.
Tales of how great drugs were brought down by a flawed rationale--letter.
Clin Cancer Res
; 19(5): 1302, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23393075
7.